Payment overview · 2025
General Payments
$1,417.81
72 reported records · 20 companies
Healthcare provider profile · identity verified
Stephen A Besson, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Adolescent Medicine · CYNTHIANA, KY · NPI 1750344552
Verified facts
What the public records show
CMS Open Payments records show Stephen A Besson, MD received $1,417.81 in general payments during 2025 across 72 reported records.
Novo Nordisk Inc accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Qulipta, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 453 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $257.55 | 18.2% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $191.01 | 13.5% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $184.56 | 13.0% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.76 | 13.0% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.22 | 9.8% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $105.68 | 7.5% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $58.97 | 4.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $58.56 | 4.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.67 | 2.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.25 | 1.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.73 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.32 | 1.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.74 | 1.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.21 | 1.4% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $17.66 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.59 | 1.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.21 | 1.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.77 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.12 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.23 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,417.81 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $191.01 | 12 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $184.56 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $172.58 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $166.99 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $157.13 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $157.13 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $141.73 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $138.22 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.19 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $58.97 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.49 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.67 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 453 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 266 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 107 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 269 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
266 | 52 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
269 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
269 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
107 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
453 | 55 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
119 | 19 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
107 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1386 | 289 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1185 | 223 |
| Gabapentin | Gabapentin | 994 | 152 |
| Omeprazole | Omeprazole | 882 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 679 | 142 |
| Lisinopril | Lisinopril | 635 | 146 |
| Losartan Potassium | Losartan Potassium | 613 | 143 |
| Carvedilol | Carvedilol | 561 | 125 |
| Furosemide | Furosemide | 544 | 131 |
| Pantoprazole Sodium | Pantoprazole Sodium | 537 | 121 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 525 | 73 |
| Metformin Hcl | Metformin Hcl | 520 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 496 | 116 |
| Alprazolam | Alprazolam | 476 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 475 | 89 |
| Eliquis | Apixaban | 453 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 437 | 78 |
| Potassium Chloride | Potassium Chloride | 434 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 394 | 64 |
| Famotidine | Famotidine | 381 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 377 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 373 | 76 |
| Trazodone Hcl | Trazodone Hcl | 315 | 60 |
| Sertraline Hcl | Sertraline Hcl | 300 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 287 | 55 |
| Jardiance | Empagliflozin | 269 | 55 |
| Buspirone Hcl | Buspirone Hcl | 267 | 52 |
| Memantine Hcl | Memantine Hcl | 267 | 51 |
| Farxiga | Dapagliflozin Propanediol | 266 | 52 |
| Donepezil Hcl | Donepezil Hcl | 263 | 40 |
| Allopurinol | Allopurinol | 261 | 49 |
| Tramadol Hcl | Tramadol Hcl | 258 | 44 |
| Montelukast Sodium | Montelukast Sodium | 254 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 248 | 86 |
| Quetiapine Fumarate | Quetiapine Fumarate | 245 | 25 |
| Clonazepam | Clonazepam | 242 | 30 |
| Xarelto | Rivaroxaban | 234 | 36 |
| Mirtazapine | Mirtazapine | 231 | 62 |
| Ropinirole Hcl | Ropinirole Hcl | 231 | 46 |
| Lorazepam | Lorazepam | 221 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 202 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 50 |
| Levetiracetam | Levetiracetam | 196 | 19 |
| Prednisone | Prednisone | 190 | 71 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 175 | 30 |
| Spironolactone | Spironolactone | 173 | 41 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 169 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 168 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 164 | 22 |
| Simvastatin | Simvastatin | 160 | 30 |
| Alendronate Sodium | Alendronate Sodium | 155 | 34 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 154 | 121 |
| Diclofenac Sodium | Diclofenac Sodium | 153 | 45 |
| Ozempic | Semaglutide | 142 | 26 |
| Pregabalin | Pregabalin | 141 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 136 | 32 |
| Metformin Hcl Er | Metformin Hcl | 133 | 26 |
| Bupropion Xl | Bupropion Hcl | 130 | 32 |
| Nystatin | Nystatin | 130 | 61 |
| Tradjenta | Linagliptin | 127 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 124 | 55 |
| Warfarin Sodium | Warfarin Sodium | 124 | 18 |
| Entresto | Sacubitril/Valsartan | 123 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 123 | 20 |
| Meloxicam | Meloxicam | 121 | 35 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 119 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 116 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 115 | 67 |
| Propranolol Hcl | Propranolol Hcl | 115 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 24 |
| Gemtesa | Vibegron | 107 | 22 |
| Temazepam | Temazepam | 107 | 14 |
| Trulicity | Dulaglutide | 107 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 107 | 25 |
| Celecoxib | Celecoxib | 106 | 30 |
| Azithromycin | Azithromycin | 105 | 78 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 103 | 102 |
| Methocarbamol | Methocarbamol | 103 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 24 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 100 | 18 |
| Cefdinir | Cefdinir | 100 | 68 |
| Diazepam | Diazepam | 100 | 23 |
| Nifedipine Er | Nifedipine | 97 | 25 |
| Divalproex Sodium | Divalproex Sodium | 96 | 12 |
| Januvia | Sitagliptin Phosphate | 96 | 14 |
| Finasteride | Finasteride | 95 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 26 |
| Ezetimibe | Ezetimibe | 94 | 23 |
| Glimepiride | Glimepiride | 92 | 24 |
| Atenolol | Atenolol | 89 | 17 |
| Synthroid | Levothyroxine Sodium | 86 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 83 | suppressed |
| Bumetanide | Bumetanide | 82 | 22 |
| Aripiprazole | Aripiprazole | 80 | 15 |
| Ibuprofen | Ibuprofen | 80 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 45 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 77 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 14 |
| Levofloxacin | Levofloxacin | 75 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 16 |
| Baclofen | Baclofen | 72 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 72 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 72 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 22 |
| Risperidone | Risperidone | 64 | suppressed |
| Invokana | Canagliflozin | 63 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 16 |
| Lovastatin | Lovastatin | 60 | 15 |
| Linzess | Linaclotide | 58 | 15 |
| Ranolazine Er | Ranolazine | 58 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 56 | 56 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 15 |
| Estradiol | Estradiol | 54 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 34 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 53 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 52 | 21 |
| Vascepa | Icosapent Ethyl | 52 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 51 | 11 |
| Fluconazole | Fluconazole | 49 | 29 |
| Topiramate | Topiramate | 49 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | 17 |
| Mupirocin | Mupirocin | 48 | 36 |
| Cephalexin | Cephalexin | 47 | 21 |
| Oxcarbazepine | Oxcarbazepine | 47 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 11 |
| Midodrine Hcl | Midodrine Hcl | 46 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 44 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 44 | 14 |
| Latanoprost | Latanoprost | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 11 |
| Rybelsus | Semaglutide | 43 | 15 |
| Vraylar | Cariprazine Hcl | 43 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 42 | 14 |
| Colchicine | Colchicine | 42 | 17 |
| Oxazepam | Oxazepam | 42 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Primidone | Primidone | 40 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Lubiprostone | Lubiprostone | 39 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 38 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Metolazone | Metolazone | 38 | 12 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 37 | suppressed |
| Carbamazepine | Carbamazepine | 36 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 35 | suppressed |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 14 |
| Olanzapine | Olanzapine | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 15 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 28 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 15 |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 20 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Erythromycin | Erythromycin Base | 32 | 17 |
| Lactulose | Lactulose | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 11 |
| Azelastine Hcl | Azelastine Hcl | 31 | 20 |
| Methylphenidate Hcl | Methylphenidate Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 19 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 29 | 11 |
| Clotrimazole | Clotrimazole | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Briviact | Brivaracetam | 26 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Kerendia | Finerenone | 26 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | 12 |
| Torsemide | Torsemide | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Phenytoin | Phenytoin | 23 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 18 |
| Verapamil Sr | Verapamil Hcl | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | 11 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 12 |
| Ramipril | Ramipril | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,417.81 · 72 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, CAPVAXIVE, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, FARXIGA, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, JARDIANCE, JOURNAVX, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ohtuvayre, Omnipod, Ozempic, PROQUAD, QULIPTA, REXULTI, Rybelsus, TONMYA, TZIELD, UBRELVY, VAXELIS, VAXNEUVANCE, VERQUVO, WATCHMAN Access System, Wegovy, ZAVZPRET, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error